Patents by Inventor Gerhard Jaehne

Gerhard Jaehne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8809358
    Abstract: The present invention relates to the use of I?B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: August 19, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Martin Michaelis, Olaf Ritzeler, Gerhard Jaehne, Karl Rudolphi, Gerd Geisslinger, Hans-Georg Schaible
  • Patent number: 8778955
    Abstract: The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of I?B kinase comprising administering such compounds.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: July 15, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Olaf Ritzeler, Gerhard Jaehne
  • Patent number: 8236810
    Abstract: The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Guenter Billen, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8163774
    Abstract: The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth DeFossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8138207
    Abstract: The present invention comprises the use of amino-carbonyl-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes, carbohydrate and lipid metabolic disorders and other blood sugar complications.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: March 20, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth DeFossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8003668
    Abstract: The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: August 23, 2011
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Publication number: 20110178134
    Abstract: The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.
    Type: Application
    Filed: August 6, 2010
    Publication date: July 21, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard JAEHNE, Siegfried STENGELIN, Matthias GOSSEL, Thomas KLABUNDE, Irvin WINKLER, Antony BIGOT, Anita DIU-HERCEND, Gilles TIRABOSCHI
  • Publication number: 20110112097
    Abstract: The invention relates to compounds of formula (I) wherein the groups R and R?, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    Type: Application
    Filed: August 6, 2010
    Publication date: May 12, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Jaehne, Peter Below, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Irvin Winkler
  • Publication number: 20110053947
    Abstract: The invention relates to compounds of formula (I) wherein the groups R and R?, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    Type: Application
    Filed: August 6, 2010
    Publication date: March 3, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard JAEHNE, Siegfried STENGELIN, Matthias GOSSEL, Thomas KLABUNDE, Irvin WINKLER
  • Publication number: 20110046105
    Abstract: The invention relates to compounds of formula (I) wherein the groups R and R?, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    Type: Application
    Filed: August 6, 2010
    Publication date: February 24, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Jaehne, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Irvin Winkler
  • Publication number: 20110046185
    Abstract: The invention relates to compounds of formula (I) wherein the groups R and R? A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    Type: Application
    Filed: August 6, 2010
    Publication date: February 24, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard JAEHNE, Peter BELOW, Siegfried STENGELIN, Matthias GOSSEL, Thomas KLABUNDE, Irvin WINKLER
  • Patent number: 7888343
    Abstract: The present invention involves substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are defined herein. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds and methods for the treatment of metabolic disorders such as type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerosis diseases and the like through the administration of said compositions.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: February 15, 2011
    Assignee: Sanofi-A Ventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7879864
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed which are inhibitors of the enzyme dipeptidyl peptidase IV (DDP-IV) and comprise novel substituted bicyclic 8-pyrrolidinoxanthines of formula I and their derivatives: wherein the various R-groups are defined herein. These compounds may be combined with other secondary active compounds which also are effective in the treatment of said disorders and the disease states or physiological manifestations arising therefrom.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: February 1, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7838528
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: November 23, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7795445
    Abstract: The present invention comprises the substituted 2-aminoalkylthiobenzimidazoles of formula I wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the treatment of type-2 diabetes.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: September 14, 2010
    Assignee: sanofi-aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7772429
    Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: August 10, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik
  • Patent number: 7763662
    Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: July 27, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Patent number: 7759366
    Abstract: This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R?, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 20, 2010
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Jaehne, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Irvin Winkler
  • Publication number: 20100160282
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: December 23, 2009
    Publication date: June 24, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Patent number: 7674773
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 9, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer